Tonix Pharmaceuticals Holding Corp.
TNXP
$12.87
-$0.29-2.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 196.02% | 74.84% | 29.85% | -8.79% | -21.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 196.02% | 74.84% | 29.85% | -8.79% | -21.09% |
| Cost of Revenue | -32.32% | 3.22% | -14.49% | -24.40% | -28.82% |
| Gross Profit | 747.67% | 243.50% | 177.67% | 50.90% | 6.99% |
| SG&A Expenses | 153.98% | 159.70% | 118.66% | 87.02% | 33.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.95% | 104.57% | 58.03% | 17.37% | -14.33% |
| Operating Income | -100.80% | -108.68% | -61.69% | -20.95% | 13.45% |
| Income Before Tax | -96.10% | -11.72% | 4.63% | 26.64% | 45.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.10% | -11.72% | 4.63% | 26.64% | 45.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.10% | -11.72% | 4.63% | 26.64% | 45.36% |
| EBIT | -100.80% | -108.68% | -61.69% | -20.95% | 13.45% |
| EBITDA | -104.38% | -114.54% | -66.54% | -25.32% | 12.00% |
| EPS Basic | 66.96% | 99.27% | 99.43% | 99.57% | 99.16% |
| Normalized Basic EPS | 66.66% | 97.23% | 98.68% | 98.11% | 96.19% |
| EPS Diluted | 66.96% | 99.27% | 99.43% | 99.57% | 99.16% |
| Normalized Diluted EPS | 66.66% | 97.23% | 98.68% | 98.11% | 96.19% |
| Average Basic Shares Outstanding | 216.29% | 371.37% | 1,048.19% | 3,413.63% | 23,332.08% |
| Average Diluted Shares Outstanding | 216.29% | 371.37% | 1,048.19% | 3,351.60% | 19,733.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |